Free Trial
NASDAQ:PACB

Pacific Biosciences of California (PACB) Stock Price, News & Analysis

Pacific Biosciences of California logo
$1.37 -0.02 (-1.44%)
Closing price 04:00 PM Eastern
Extended Trading
$1.37 0.00 (0.00%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Pacific Biosciences of California Stock (NASDAQ:PACB)

Key Stats

Today's Range
$1.35
$1.44
50-Day Range
$0.91
$1.58
52-Week Range
$0.85
$2.72
Volume
4.38 million shs
Average Volume
9.61 million shs
Market Capitalization
$411.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.06
Consensus Rating
Hold

Company Overview

Pacific Biosciences of California Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
37th Percentile Overall Score

PACB MarketRank™: 

Pacific Biosciences of California scored higher than 37% of companies evaluated by MarketBeat, and ranked 730th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for Pacific Biosciences of California are expected to grow in the coming year, from ($0.72) to ($0.59) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Pacific Biosciences of California is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Pacific Biosciences of California is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Pacific Biosciences of California has a P/B Ratio of 0.74. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Pacific Biosciences of California's valuation and earnings.
  • Percentage of Shares Shorted

    16.19% of the float of Pacific Biosciences of California has been sold short.
  • Short Interest Ratio / Days to Cover

    Pacific Biosciences of California has a short interest ratio ("days to cover") of 5.1.
  • Change versus previous month

    Short interest in Pacific Biosciences of California has recently increased by 19.50%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Pacific Biosciences of California does not currently pay a dividend.

  • Dividend Growth

    Pacific Biosciences of California does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    16.19% of the float of Pacific Biosciences of California has been sold short.
  • Short Interest Ratio / Days to Cover

    Pacific Biosciences of California has a short interest ratio ("days to cover") of 5.1.
  • Change versus previous month

    Short interest in Pacific Biosciences of California has recently increased by 19.50%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Pacific Biosciences of California has a news sentiment score of 1.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.96 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Pacific Biosciences of California this week, compared to 4 articles on an average week.
  • Search Interest

    12 people have searched for PACB on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added Pacific Biosciences of California to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
Receive PACB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pacific Biosciences of California and its competitors with MarketBeat's FREE daily newsletter.

PACB Stock News Headlines

Utah’s New Oil Find
The Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle of the Utah's Black Desert. Why? Not for oil discovery. Or uranium or solar. Instead, what’s happening beneath this patch of sand is the discovery of a new kind of energy. Google, Buffett, and a even tech billionaires like Gates, Bezos, and Zuckerberg are grabbing a stake.
See More Headlines

PACB Stock Analysis - Frequently Asked Questions

Pacific Biosciences of California's stock was trading at $1.83 at the start of the year. Since then, PACB stock has decreased by 25.1% and is now trading at $1.37.

Pacific Biosciences of California, Inc. (NASDAQ:PACB) posted its quarterly earnings data on Thursday, May, 8th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.04. The biotechnology company had revenue of $37.15 million for the quarter, compared to analysts' expectations of $36.90 million. Pacific Biosciences of California had a negative trailing twelve-month return on equity of 52.07% and a negative net margin of 430.93%.
Read the conference call transcript
.

Pacific Biosciences of California subsidiaries include these companies: Circulomics, Omniome, PacBio Singapore PTE Limited, Pacific Biosciences Canada Limited, Pacific Biosciences Germany GmbH, Pacific Biosciences Japan GK, Pacific Biosciences (Shanghai) Co. Ltd., Pacific Biosciences UK Limited, and Pacific Biosciences International LLC.

Pacific Biosciences of California's top institutional shareholders include Mirador Capital Partners LP (0.19%), AdvisorNet Financial Inc (0.04%) and Wealth Enhancement Advisory Services LLC (0.01%). Insiders that own company stock include Oene Mark Van, Christian O Henry, Jeff Eidel, Susan G Kim, Michele Farmer and William W Ericson.
View institutional ownership trends
.

Shares of PACB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pacific Biosciences of California investors own include Tesla (TSLA), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Alphabet (GOOG).

Company Calendar

Last Earnings
5/08/2025
Today
7/18/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED INSTRUMENTS
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NASDAQ:PACB
CIK
1299130
Employees
730
Year Founded
2004

Price Target and Rating

High Price Target
$3.50
Low Price Target
$1.25
Potential Upside/Downside
+48.8%
Consensus Rating
Hold
Rating Score (0-4)
2.44
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.79)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$309.85 million
Net Margins
-430.93%
Pretax Margin
-431.71%
Return on Equity
-52.07%
Return on Assets
-15.82%

Debt

Debt-to-Equity Ratio
7.05
Current Ratio
6.68
Quick Ratio
5.87

Sales & Book Value

Annual Sales
$154.01 million
Price / Sales
2.70
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.85 per share
Price / Book
0.75

Miscellaneous

Outstanding Shares
300,080,000
Free Float
292,583,000
Market Cap
$415.61 million
Optionable
Optionable
Beta
2.16

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:PACB) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners